Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Launched by ANHUI PROVINCIAL HOSPITAL · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called letermovir on patients who have received an unrelated cord blood transplant (UCBT) and are at risk for a virus called cytomegalovirus (CMV). CMV can become active again after a transplant, which is why the researchers want to see if letermovir can help the immune system recover and fight off the virus better after the transplant.

To participate in this trial, patients must be receiving their first unrelated cord blood transplant and start taking letermovir within 28 days after the transplant. However, patients who already have the CMV virus in their blood when they start the medication or who are part of another clinical study focused on anti-CMV treatments cannot join. Participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. This trial is currently looking for new participants, and everyone, regardless of gender, is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients are receiving a first unrelated cord blood transplantation (UCBT).
• • Patients start letemovir prophylaxis within 0-28 days post UCBT.
• Exclusion Criteria:
• • Patients having active CMV DNAemia at the time of letermovir initiation.
• • Patients recruited in a clinical study on an anti-CMV trial.